Compare OPY & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPY | NBTX |
|---|---|---|
| Founded | 1881 | 2003 |
| Country | United States | France |
| Employees | 2973 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 956.2M | 1.0B |
| IPO Year | 1996 | 2018 |
| Metric | OPY | NBTX |
|---|---|---|
| Price | $86.00 | $31.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | ★ 49.8K | 20.7K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | ★ 104.71 | N/A |
| EPS | ★ 13.04 | N/A |
| Revenue | ★ $1,638,071,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $11.73 |
| P/E Ratio | $13.82 | ★ N/A |
| Revenue Growth | ★ 14.35 | N/A |
| 52 Week Low | $49.26 | $2.95 |
| 52 Week High | $94.10 | $30.23 |
| Indicator | OPY | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.84 | 73.91 |
| Support Level | $84.00 | $20.11 |
| Resistance Level | $94.10 | N/A |
| Average True Range (ATR) | 3.04 | 1.61 |
| MACD | -0.52 | 0.46 |
| Stochastic Oscillator | 19.81 | 97.92 |
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.